BioCina Expands Global Footprint with NovaCina Merger

BioCina, a Contract Development and Manufacturing Organization (CDMO), has announced a merger with NovaCina to strengthen their global presence in biopharmaceutical manufacturing. The merged company, which will retain the BioCina name, will offer end-to-end development services encompassing cell line and process development, clinical to commercial active pharmaceutical ingredients (APIs), and sterile fill-finish of small molecules. The union incorporates BioCina's expertise in microbial modality, plasmid DNA, and mRNA at its Adelaide location with NovaCina's advanced sterile fill-finish facility in Perth. Under the leadership of CEO Mark W. Womack, the newly integrated entity aims to provide high-quality, integrated manufacturing solutions responsive to client needs worldwide. BioCina's proven regulatory track record includes approvals from global entities like the FDA and EMA, and it highlights Australia's attractive fiscal incentives for CDMOs. The merger targets the increasing demand for integrated manufacturing solutions in the evolving biopharmaceutical sector.